Created for it
Developed with your patient's quality of life in mind
As your trusted partner in cardiac surgery innovation, Edwards Lifesciences has developed the MITRIS RESILIA mitral valve to help meet the specialized needs of your patients.
Developed with your patient's quality of life in mind
A saddle-shaped sewing cuff mimics the native mitral annulus
Handles the pressure of the mitral position
for easy identification of the landing zone for potential future transcatheter interventions.
to eliminate need for rinsing.
do not obstruct blood flow through the left ventricular outflow tract (LVOT).
^On a label size 25 mm. Anterior Profile Height.
Backed by a strong and growing body of clinical evidence supported by RESILIA tissue’s ongoing study of durability and hemodynamic performance 1, 2, 3, 4
Clinically stable hemodynamics and one incident of structural valve deterioration (SVD) through 5 years.
Clinically stable hemodynamics and two incidents of SVD through 7 years.
Clinically stable hemodynamics and zero SVD through 5 years in 133 patients.
The MITRIS mitral valve is made with RESILIA tissue for decreased calcification*, this is the mitral valve developed with your patient's quality of life in mind.
* No clinical data are available that evaluate the long-term impact of RESILIA tissue in patients. Additional clinical data for up to 10 years of follow-up are being collected to monitor the long-term safety and performance of RESILIA tissue.
The MITRIS RESILIA mitral valve, Model 11400M is indicated for the replacement of native or prosthetic mitral heart valves.
The MITRIS valve features RESILIA tissue and is treated with a special integrity preservation technology that effectively eliminates free aldehydes while protecting and preserving tissue.
No clinical data are available that evaluate the long-term impact of RESILIA tissue in patients. Additional clinical data for up to 10 years of follow-up are being collected to monitor the long-term safety and performance of RESILIA tissue.
We are committed to providing your institution, clinicians and staff with the highest levels of customer service and support to ensure seamless product implementation and ongoing use, including:
Monday through Friday, 8:00am to 17:00pm CET
* No clinical data are available that evaluate the long-term impact of RESILIA tissue in patients. Additional clinical data for up to 10 years of follow-up are being collected to monitor the long-term safety and performance of RESILIA tissue.
For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).